Aileron $12M Raise to Propel Stapled Peptide into Clinic
By Marie Powers
Tuesday, January 15, 2013
Aileron Therapeutics Inc. secured a second tranche of $12 million in its Series D financing, bringing the total round to $42 million and positioning its lead stapled peptide drug, ALRN-5281, to enter the clinic in orphan endocrine disorders.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.